中国高胆固醇血症患者的tafololecimab (CREDIT-4):一个随机,双盲,安慰剂控制的第三期试验
Litong Qi1, Dexue Liu2, Yanling Qu3
1Department of Cardiology, Peking University First Hospital, Beijing, China.
在患有高胆固醇血症的中国患者中,tafolecimab显著降低了LDL-C. 这种新型的proprotein转化酶亚素/素9型 (PCSK9) 抗体显示出强大的疗效和良好的安全性.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 塔福莱奇马布是一种新型,全人类单克隆抗体,向9型 (PCSK9) 蛋白转化酶亚提利辛/素.
- 它是为治疗高胆固醇血症而开发的,这种疾病的特征是高胆固醇水平.
研究的目的:
- 评估tafolecimab在中国患者中的疗效和安全性.
- 这项研究的重点是高胆固醇血症患者,他们有高或非常高的心血管风险.
主要方法:
- 一项随机,双盲,安慰剂控制的研究进行了12周.
- 患者每4周接受tafolecimab或安慰剂,主要终点是LDL-C从基线到第12周的百分比变化.
主要成果:
- 与安慰剂 (-5.8%) 相比,tafolecimab治疗导致LDL-C水平显著降低 (-68.9%).
- 在接受tafolecimab的患者中,更大比例的患者实现了目标的LDL-C降低和水平 (<1.8 mmol/L和<1.4 mmol/L).
- 塔福利西马布也有效地降低了非HDL-C,非脂蛋白B和脂蛋白a水平,通常有轻微的不良反应.
结论:
- 在高心血管风险的高胆固醇血症中国患者中,tafolecimab表现出强大的降脂效果.
- 在研究期间,tafolecimab的安全概况是有利的.
更多相关视频
10:56A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
Published on: September 15, 2018
09:39Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
Published on: September 17, 2019
相关概念视频
Atherosclerosis III: Management
Clinical Trials
There are four phases in a clinical trial. A phase one...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Clinical Trials: Overview
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
